User:Mr. Ibrahem/Ixekizumab

Ixekizumab, sold under the brand name Taltz, is a medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. For plaque psoriasis it is used for moderate to severe disease. It is given as an injection under the skin.

Common side effects include respiratory infections and injection site pain. Other side effects may include infections and allergic reactions. Safety in pregnancy is unclear. It is a monoclonal antibody that attaches to and blocks interleukin 17A, reducing inflammation.

Ixekizumab was approved for medical use in the Europe and the United States in 2016. In the United Kingdom it costs the NHS about £1,130 per 80 mg dose as of 2021. In the United States this amount costs about 6,250 USD.